Nature's Sunshine Products Inc (NATR): Total Liabilities
$99.59M
As of 2025-12-31
$90.51M
As of 2026-06-30
+6.4%
3-year compound annual growth
+1.5%
5-year compound annual growth
+4.5%
10-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $99.59M | +24.7% | 2026-03-10, Balance as of period end |
| 2024-12-31 | $79.86M | -11.5% | 2026-03-10, Balance as of period end |
| 2023-12-31 | $90.23M | +9.1% | 2025-03-11, Balance as of period end |
| 2022-12-31 | $82.73M | -15.1% | 2024-03-12, Balance as of period end |
| 2021-12-31 | $97.47M | +5.6% | 2023-03-16, Balance as of period end |
| 2020-12-31 | $92.26M | +10.3% | 2022-03-08, Balance as of period end |
| 2019-12-31 | $83.63M | +15.4% | 2021-03-10, Balance as of period end |
| 2018-12-31 | $72.45M | -4.0% | 2020-03-11, Balance as of period end |
| 2017-12-31 | $75.46M | +3.1% | 2019-03-08, Balance as of period end |
| 2016-12-31 | $73.17M | +13.9% | 2018-03-16, Balance as of period end |
| 2015-12-31 | $64.25M | -5.3% | 2017-03-14, Balance as of period end |
| 2014-12-31 | $67.84M | -28.1% | 2016-03-14, Balance as of period end |
| 2013-12-31 | $94.35M | n/a | 2015-03-13, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $99.59M | +24.7% |
| Travere Therapeutics, Inc. (TVTX) | 2025-12-31 | $490.36M | -8.4% |
| BridgeBio Pharma, Inc. (BBIO) | 2025-12-31 | $3.01B | +26.7% |
| Zai Lab Ltd (ZLAB) | 2025-12-31 | $456.88M | +32.5% |
| Mirum Pharmaceuticals, Inc. (MIRM) | 2025-12-31 | $528.12M | +18.6% |
| HUTCHMED (China) Ltd (HCM) | 2025-12-31 | $501.83M | -0.1% |
| Organogenesis Holdings Inc. (ORGO) | 2025-12-31 | $164.81M | +46.4% |
| Ardelyx, Inc. (ARDX) | 2025-12-31 | $334.65M | +27.5% |
| Sinovac Biotech Ltd (SVA) | 2025-12-31 | $2.15B | +5.0% |
Compare NATR, TVTX, BBIO, ZLAB side by side · Screen every company in Pharmaceutical Preparations ↗